AU2001278115A1 - Formulations of mometasone and a bronchodilator for pulmonary administration - Google Patents

Formulations of mometasone and a bronchodilator for pulmonary administration

Info

Publication number
AU2001278115A1
AU2001278115A1 AU2001278115A AU7811501A AU2001278115A1 AU 2001278115 A1 AU2001278115 A1 AU 2001278115A1 AU 2001278115 A AU2001278115 A AU 2001278115A AU 7811501 A AU7811501 A AU 7811501A AU 2001278115 A1 AU2001278115 A1 AU 2001278115A1
Authority
AU
Australia
Prior art keywords
bronchodilator
mometasone
formulations
pulmonary administration
pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278115A
Other languages
English (en)
Inventor
Theodore L. Iorio
Leonard W. Kaplan
Karl P Weinrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Longwood Pharmaceutical Research Inc
Original Assignee
Longwood Pharmaceutical Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Longwood Pharmaceutical Research Inc filed Critical Longwood Pharmaceutical Research Inc
Publication of AU2001278115A1 publication Critical patent/AU2001278115A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001278115A 2000-08-04 2001-08-01 Formulations of mometasone and a bronchodilator for pulmonary administration Abandoned AU2001278115A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22354100P 2000-08-04 2000-08-04
US60/223,541 2000-08-04
PCT/US2001/024093 WO2002011711A2 (en) 2000-08-04 2001-08-01 Formulations of mometasone and a bronchodilator for pulmonary administration

Publications (1)

Publication Number Publication Date
AU2001278115A1 true AU2001278115A1 (en) 2002-02-18

Family

ID=22836952

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278115A Abandoned AU2001278115A1 (en) 2000-08-04 2001-08-01 Formulations of mometasone and a bronchodilator for pulmonary administration

Country Status (5)

Country Link
US (2) US20020076382A1 (de)
EP (1) EP1311294A2 (de)
AU (1) AU2001278115A1 (de)
CA (1) CA2417973A1 (de)
WO (1) WO2002011711A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6182712B1 (en) 1997-07-21 2001-02-06 Inhale Therapeutic Systems Power filling apparatus and methods for their use
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
WO2002080859A2 (en) * 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
SK286394B6 (sk) * 2001-03-30 2008-09-05 Jagotec Ag Lekárske aerosólové prípravky
EP1414468B1 (de) * 2001-08-07 2004-12-15 Galephar M/F Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
KR20050003416A (ko) * 2002-05-07 2005-01-10 넥타르 테라퓨틱스 건조분말 흡입기용 캡슐 및 이의 제조 및 사용 방법
TR200201343A2 (tr) * 2002-05-17 2003-12-22 Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. Kortikosteroid ve antiseptik içeren farmasötik bileşim
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040060265A1 (en) * 2002-06-27 2004-04-01 Nektar Therapeutics Controlling the flow of a powder
WO2004018025A1 (en) * 2002-08-23 2004-03-04 Schering Corporation Pharmaceutical compositions
MXPA05002248A (es) * 2002-08-27 2005-06-08 Schering Corp Procedimiento para producir formulaciones de inhalador de dosis medida.
US20040043064A1 (en) * 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission
US20040191176A1 (en) * 2003-03-28 2004-09-30 Kaplan Leonard W Formulations for treatment of pulmonary disorders
EP2792353B1 (de) * 2003-05-22 2018-02-28 United Therapeutics Corporation Polymorph von Treprostinil-Diethanolaminsalz
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
SE526850C2 (sv) * 2003-06-19 2005-11-08 Microdrug Ag Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
CA2542530A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical aerosol compositions
EP1809243B2 (de) * 2004-07-02 2022-06-08 Boehringer Ingelheim International GmbH Aerosolsuspensionsformulierungen mit tg 227 ea als treibmittel
US20070264202A1 (en) * 2004-09-09 2007-11-15 Cipla Limited Pharmaceutical Composition Comprising an Isomer of Betamimetic Agent and an Anti-Cholinergic Agent
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
DK2522365T3 (en) 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
RU2440972C2 (ru) * 2004-12-17 2012-01-27 Сипла Лимитед Кристаллический сульфат левосальбутамола, способ его получения и фармацевтическая композиция, содержащая его
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP1844805A1 (de) * 2006-04-13 2007-10-17 Boehringer Ingelheim Pharma GmbH & Co.KG Inhalator
GB0616299D0 (en) * 2006-08-16 2006-09-27 Cambridge Consultants Drug Capsules for dry power inhalers
EP2230934B8 (de) 2007-12-14 2012-10-24 AeroDesigns, Inc Abgabe von aerosol-sprühbaren nahrungsmittelprodukten
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2012058719A1 (en) * 2010-11-02 2012-05-10 The Universtity Of Sydney Inhalable compositions
US20140011784A1 (en) * 2011-11-17 2014-01-09 Jonathan Matz Method and composition for treating asthma
KR101342199B1 (ko) 2012-02-27 2013-12-16 전진우 캡슐형 주사기 조립체
US20150335695A1 (en) * 2014-05-25 2015-11-26 Tu Song-Anh Nguyen Therapeutic Nutritional Supplement to Alleviate Symptoms of COPD and Delay the Progression Thereof
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2017146994A1 (en) * 2016-02-24 2017-08-31 Merck Sharp & Dohme Corp. Controlled agglomeration of micronized drug or drug-excipient mixtures

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3260474D1 (en) * 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US5126133A (en) * 1989-06-27 1992-06-30 Mycogen Corporation Bacillus thuringiensis isolate active against lepidopteran pests, and genes encoding novel lepidopteran-active toxins
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
PT101988B (pt) * 1997-04-04 2004-02-27 Hovione Farmaciencia Sa Sistema de orientacao e posicionamento de um objecto
US5837399A (en) * 1997-07-22 1998-11-17 Hughes Electronics Corporation Through-wall electrical terminal and energy storage cell utilizing the terminal
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
GB0009609D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic compositions
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
SE0004750D0 (sv) * 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo

Also Published As

Publication number Publication date
WO2002011711A3 (en) 2003-02-27
EP1311294A2 (de) 2003-05-21
US20040198708A1 (en) 2004-10-07
WO2002011711A2 (en) 2002-02-14
US20020076382A1 (en) 2002-06-20
CA2417973A1 (en) 2002-02-14
WO2002011711B1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
AU2001278115A1 (en) Formulations of mometasone and a bronchodilator for pulmonary administration
AU2001226029A1 (en) Pharmaceutical formulation and method for pulmonary and oral delivery
AU2001231000A1 (en) Dry powder formulations of antihistamine for nasal administration
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
AU2001224716A1 (en) A medicinal aerosol formulation
AU2001226233A1 (en) A medicinal aerosol formulation
AU2002225855A1 (en) Preparation of nanocrystallites
AU2001280188A1 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AU2001294920A1 (en) Chrono delivery formulations and method of use thereof
AU2001280908A1 (en) Rotavirus vaccine formulations
AU2001279156A1 (en) Manufacture and use of a herbicide formulation
HUP0302311A3 (en) Medicinal aerosol formulations
AU2001289102A1 (en) Topical formulations for delivery of interleukin-11
AU2001284444A1 (en) Preparations for oral administration
AU2002234545A1 (en) Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
AU2001272314A1 (en) Oral formulations for localized colonic release and the method of preparation thereof
AU2001222986A1 (en) Dehydroascorbic acid formulations and uses thereof
AU2002216346A1 (en) Cabergoline pharmaceutical compositions and methods of use thereof
AU2002211660A1 (en) Ginseng berry extracts and pharmaceutical compositions therefrom
AU2001224718A1 (en) A medicinal aerosol formulation
AU2001230898A1 (en) Formulations and methods for administration of pharmacologically or biologicallyactive compounds
AU2001259318A1 (en) A medicinal aerosol formulation
AU2002219249A1 (en) Enteric-coated drug formulations and their manufacture
AU1141101A (en) Pharmaceutical aerosol formulations comprising s-salmeterol
AU2002212327A1 (en) Pharmaceutical preparation comprised of milk-thistle and terpenes